FCM
TBPH icon

Flinton Capital Management’s Theravance Biopharma TBPH Stock Holding History

Flinton Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$48K Buy
2,448
+1,700
+227% +$34.3K ﹤0.01% 824
2019
Q2 		$12K Hold
748
– – ﹤0.01% 872
2019
Q1 		$17K Hold
748
– – ﹤0.01% 855
2018
Q4 		$19K Buy
+748
New +$20.2K ﹤0.01% 830

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Flinton Capital Management's TBPH Position: Q3 2019 in Review

Flinton Capital Management increased its Theravance Biopharma (TBPH) stake by 227% in Q3 2019, buying an estimated $34.3K and bringing the position to 2,448 shares worth $48K. The position accounts for ﹤0.01% of the portfolio, ranked #824.

Flinton Capital Management first reported a position in TBPH in Q4 2018 and has held it in 4 quarters since. 92 funds tracked by Wall St. Rank hold TBPH as of Q3 2019.

  • Flinton Capital Management held 2,448 shares of Theravance Biopharma worth $48K as of Q3 2019.
  • Flinton Capital Management bought 1,700 Theravance Biopharma shares in Q3 2019, an estimated $34.3K.
  • Theravance Biopharma made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #824 holding.
  • Flinton Capital Management first reported a position in Theravance Biopharma in Q4 2018 and has held it in 4 quarters since.
  • 92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.